EGFR and non-small cell lung carcinoma: The literature reported that ipilimumab plus erlotinib and gefitinib plus tremelimumab caused excessive gastrointestinal toxicity in advanced NSCLC patients with EGFR mutation, preventing further evaluation of this combination [107, 108].